54856 Federal Register / Vol. 62, No. 204 / Wednesday, October 22, 1997 / Notices

determination is contained in section

337 of the Tariff Act of 1930, as

amended (19 U.S.C. 1337), and in

section 210.50 of the Commission’s

Rules of Practice and Procedure (19 CFR

210.50).

The Commission instituted this

investigation on November 22, 1996,

based on a complaint filed by The

Procter & Gamble Company (P&G)

concerning allegations of unfair acts in

violation of section 337 in the

importation and sale of certain

toothbrushes covered by U.S. Letters

Patent Des. 328,392. The complaint, as

amended, also alleged copyright

infringement by certain respondents,

but those allegations were subsequently

withdrawn from the investigation.

The Commission found Shummi

Enterprise Co., Ltd (Shummi) and

Shumei Industrial Co., Ltd. (Shumei) in

violation of section 337 and found

Giftline International Corporation

(Giftline) in default for failure to

respond to the complaint and notice of

investigation.

On July 2, 1997, the presiding

administrative law judge (ALJ) issued a

recommended determination (RD) on

the issues of remedy and bonding for

respondents Shummi and Shumei. The

ALJ recommended a limited exclusion

order and a bond in the amount of 100

percent of entered value during the 60-

day Presidential review period.

On August 20, 1997, the Commission

published a notice requesting written

submissions on the issues of remedy,

the public interest, and bonding. The

Commission investigative attorney and

complainant P&G filed submissions on

these issues, essentially concurring with

the ALJ’s recommendations as to

Shumei and Shummi and arguing for

the same remedy and bond to apply to

Giftline. No other submissions were

filed.

Having reviewed the record in this

investigation, including the parties’

written submissions, the Commission

determined that the appropriate form of

relief is a limited exclusion order

prohibiting the unlicensed entry of

infringing toothbrushes that are

manufactured abroad by or on behalf of

Shummi, Shumei, or Giftline. The

Commission further determined that the

public interest factors enumerated in

subsection 337(d) do not preclude

issuance of the limited exclusion order,

and that the bond during the

Presidential review period shall be in

the amount of one hundred (100)

percent of the entered value of the

articles in question.

Copies of the Commission’s order, the

public version of the Commission’s

opinion in support thereof, and all other

nonconfidential documents filed in

connection with this investigation are or

will be available for inspection during

official business hours (8:45 a.m. to 5:15

p.m.) in the Office of the Secretary, U.S.

International Trade Commission, 500 E

Street, S.W., Washington, D.C. 20436,

telephone (202) 205–2000. Hearing

impaired persons are advised that

information on the matter can be

obtained by contacting the

Commission’s TDD terminal at 202–

205–1810.

Issued: October 15, 1997.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 97–27938 Filed 10–21–97; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on June 6, 1997, Arenol

Corporation, 189 Meister Avenue,

Somerville, New Jersey 08876, made

application by renewal to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Methamphetamine (1105) ............ II

Phenylacetone (8501) .................. II

The firm plans to import the listed

controlled substances to manufacture

pharmaceutical products.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than November 21, 1997.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: October 7, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–27894 Filed 10–21–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on September

10, 1997, Norac Company, Inc., 405 S.

Motor Avenue, Azusa, California 91702,

made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

tetrahydrocannabinols (7370) a basic

class of controlled substance listed in

Schedule I.

The firm plans to manufacture

medication for the treatment of AIDS

wasting syndrome and as an antiemetic.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug